LGD-3303(CAT: I011845) is a selective androgen receptor modulator (SARM) with excellent oral bioavailability. It has been studied as a possible treatment for osteoporosis and has been shown in animal studies to improve the effectiveness of bisphosphonate drugs. This product is used for medical research and development and other scientific research purposes.
| Catalog Number | I011845 |
| CAS Number | 917891-35-1 |
| Synonyms | LGD 3303; 9-Chloro-2-ethyl-3,6-dihydro-1-methyl-3-(2,2,2-trifluoroethyl)-7H-pyrrolo[3,2-f]quinolin-7-one; |
| Molecular Formula | C16H14ClF3N2O |
| Purity | 95% |
| Target | Androgen receptor |
| Storage | RT |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>LGD-3303 is a selective androgen receptor modulator. It has been granted for the new molecular entity. </span></span></span> |
| IUPAC Name | 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-6H-pyrrolo[3,2-f]quinolin-7-one |
| InChI | InChI=1S/C16H14ClF3N2O/c1-3-11-8(2)14-12(22(11)7-16(18,19)20)5-4-10-15(14)9(17)6-13(23)21-10/h4-6H,3,7H2,1-2H3,(H,21,23) |
| InChIKey | OMXGOGXEWUCLFI-UHFFFAOYSA-N |
| SMILES | CCC1=C(C2=C(N1CC(F)(F)F)C=CC3=C2C(=CC(=O)N3)Cl)C |
| Reference | 1: Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O/'Brien Z, Chang WY, Meglasson MD, Lee YH. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7( 6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J Pharmacol Exp Ther. 2009 Feb;328(2):663-70. doi: 10.1124/jpet.108.146811. Epub 2008 Nov 18. PubMed PMID: 19017848. |
